DETECTING ADALIMUMAB SERUM LEVEL AND ANTI-DRUG ANTIBODIES - FUTURE TOOL IN MONITORING SPONDYLOARTHRITIS PATIENTS?

被引：1
|
作者：
Deaconu, C. [1 ]
Opris, D. [1 ,2 ]
Mazilu, D. [1 ,2 ]
Borangiu, A. [1 ,2 ]
Groseanu, L. [1 ,2 ]
Negru, M. [1 ,2 ]
Constantinescu, C. [1 ,2 ]
Saulescu, I. [1 ,2 ]
Bojinca, V. [1 ,2 ]
Vlad, V. [1 ]
Balanescu, A. [1 ,2 ]
Predeteanu, D. [1 ,2 ]
Ionescu, R. [1 ,2 ]
机构：
[1] SfantaMaria Clin Hosp, Dept Rheumatol & Internal Med, Bucharest, Romania
[2] Univ Med & Pharm Carol Davila, Bucharest, Romania
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-209124.178
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A10.06
引用
收藏
页码：A75 / A75
页数：1
相关论文
共 50 条
  • [1] Therapeutic Drug Monitoring of the Biosimilar (AMJEVITA™, Adalimumab-atto) Using Labcorp Adalimumab Assay for Drug Level and Anti-Drug Antibodies
    Chun, Kelly Y.
    Bastidas, Monique
    Yeo, Lythou
    Magpantay, Susie
    Scott, Judah
    Zikry, Michael
    Galdamez, Wayne
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S5 - S6
  • [2] Long Persistence of Anti-Drug Antibodies in Adalimumab Treated RA Patients
    Kekow, Joern
    Drynda, Susanne
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [3] ADALIMUMAB SERUM DRUG LEVELS AND ANTI-DRUG ANTIBODIES: ASSOCIATION TO DISEASE ACTIVITY AND DRUG SURVIVAL IN INFLAMMATORY ARTHRITIS PATIENTS
    Jyssum, I.
    Gehin, J. E.
    Kristianslund, E.
    Sexton, J.
    Worren, D.
    Hu, Y.
    Kvien, T. K.
    Haavardsholm, E. A.
    Bolstad, N.
    Syversen, S. W.
    Goll, G. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 421 - 422
  • [4] MONITORING OF TNF-ALPHA BLOCKERS INFLIXIMAB AND ADALIMUMAB BY MEASURING TROUGH LEVEL CONCENTRATIONS AND ANTI-DRUG ANTIBODIES
    Westerlund, Johanna
    Jokiranta, T. Sakari
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2012, 41 (04) : 325 - 325
  • [5] Adalimumab Serum Concentrations or Anti-Drug Antibodies Do Not Influence Fatigue in Patients with Crohn's Disease
    Karlsen, Lars Normann
    Carlsen, Arne
    Omdal, Roald
    Aabakken, Lars
    Bolstad, Nils
    Lundin, Knut
    Grimstad, Tore
    INFLAMMATORY BOWEL DISEASES, 2017, 23 : S44 - S45
  • [6] DIFFERENCES IN SERUM DRUG LEVELS AND ANTI-DRUG ANTIBODIES IN PATIENTS WITH INFLAMMATORY ARTHRITIS TREATED WITH ORIGINATOR VS BIOSIMILAR ADALIMUMAB
    Jyssum, I.
    Gehin, J. E.
    Kristianslund, E.
    Sexton, J.
    Worren, D.
    Hu, Y.
    Kvien, T. K.
    Haavardsholm, E. A.
    Bolstad, N.
    Syversen, S. W.
    Goll, G. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 362 - 363
  • [7] Factors that may influence the development of anti-drug antibodies to adalimumab
    Reinisch, W.
    Rauter, I.
    Chen, L.
    Gessner, M.
    Fanjiang, G.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S429 - S430
  • [8] Adalimumab/infliximabDevelopment of anti-drug antibodies: 7 case reports
    Reactions Weekly, 2018, 1701 (1) : 15 - 15
  • [9] Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service
    Nice, R.
    Chanchlani, N.
    Green, H.
    Bewshea, C.
    Kennedy, N.
    Ahmad, T.
    Goodhand, J.
    McDonald, T.
    Perry, M.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S018 - S019
  • [10] Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
    Jyssum, Ingrid
    Gehin, Johanna E.
    Sexton, Joseph
    Kristianslund, Eirik Klami
    Hu, Yi
    Warren, David John
    Kvien, Tore K.
    Haavardsholm, Espen A.
    Syversen, Silje Watterdal
    Bolstad, Nils
    Goll, Guro Lovik
    RHEUMATOLOGY, 2024, 63 (06) : 1746 - 1755
12345